Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).
Previously, the product was approved for growth failure in children due to inadequate endogenous growth hormone (GH) secretion and for the replacement of endogenous GH in adults with GH deficiency.
The patient disclosed that she had been taking a biotin supplement, and after comprehensive workup, including a scheduled surgical procedure, abnormalities were attributed to biotin interference.
The study's primary objectives will be to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior and body weight in patients with Prader-Willi syndrome
A new review published in the Journal of Neurosurgery: Spine details the health issues that troubled JFK the most, specifically his back. His low-back pain was instigated by a football injury sustained while he was at Harvard in 1937. An orthopedic spine specialist diagnosed him in 1940 with a "very unstable lumbosacral joint".
The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company.
The Task Force that authored the Society's statement aimed to review the different forms of endocrine hypertension, focusing on prevalence, clinical presentation, recommendations on when to perform case detection testing, and available case-detection tests.
Hypothalamic amenorrhea occurs when the hypothalamus slows or stops releasing GnRH, a hormone that controls the menstrual cycle. It can increase the risk of other health issues such as delayed puberty in adolescents and infertility in female adults.
The Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society have updated the 2003 guideline for growth hormone and insulin-like growth factor-I (IGF-I) treatment in children and adolescents.
In a case report published online April 7 in Pediatrics, iatrogenic Cushing's syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.
Use of aromatase inhibitors for up to 3 years in combination with growth hormone may be an effective and safe option to help very short adolescent boys grow taller, a study presented at ENDO 2016 has found.
The Food and Drug Administration (FDA) announced it is requiring class-wide safety labeling changes for all immediate-release (IR) opioid pain medicines.
Ipsen announced that in collaboration with the Food and Drug Administration (FDA), it is releasing an additional batch of Increlex (mecasermin [rDNA origin]).
The first study in the United States to investigate the long-term outcomes of medical treatment for transgender youth is set to begin in the near future after having been awarded $5.7 million by the National Institutes of Health (NIH).
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved FlexPro PenMate, which is intended for patients who use Norditropin (somatropin [rDNA origin]) FlexPro 5mg, 10mg, and 15mg pens and prefer hidden needles during their injection.
An IGF2 variant (c.191C→A, p.Ser64Ter) affects postnatal as well as prenatal growth among those who have inherited the variant through paternal transmission, according to a report published in the New England Journal of Medicine.
Chiasma announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for octreotide capsules for the maintenance treatment of adults with acromegaly.
For patients with transsphenoidal pituitary tumors, hospital charges, costs, and length of stay are increased with lower-volume surgeons, according to a study presented at the annual meeting of the American Association of Neurological Surgeons.
Serious adverse drug reactions (ADRs) can occur after bromocriptine use in lactation inhibition, most of which could be avoided, according to a new study.
Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).
Ipsen, in collaboration with the FDA is releasing a third batch of Increlex (mecasermin [rDNA origin]), since the initial resumption of product supply in May 2014.